Patents by Inventor Eckhard Günther

Eckhard Günther has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyridopyrazine derivatives and their use
    Patent number: 8937068
    Abstract: Pyridopyrazine compounds which are suitable for the treatment or prevention of physiological and/or pathophysiological states mediated and/or modulated by signal transduction pathways and/or enzymes in mammals and in particular in humans.
    Type: Grant
    Filed: November 10, 2006
    Date of Patent: January 20, 2015
    Assignee: Zentaris GmbH
    Inventors: Irene Seipelt, Eckhard Claus, Eckhard Guenther, Tilmann Schuster, Michael Czech, Emmanuel Polymeropoulos
  • Pyridopyrazine derivatives and their use
    Patent number: 8912189
    Abstract: The present invention provides new pyridopyrazine compounds of Formula (I) which are suitable for the treatment or prevention of physiological and/or pathophysiological states mediated and/or modulated by signal transduction pathways and/or enzymes in mammals and in particular in humans.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: December 16, 2014
    Assignee: Aeterna Zentaris GmbH
    Inventors: Matthias Gerlach, Irene Seipelt, Lars Blumenstein, Gilbert Mueller, Eckhard Guenther, Tilmann Schuster, Michael Teifel
  • Pyridopyrazines as highly selective ras-Raf-Mek-Erk signal transduction pathway inhibitors
    Patent number: 8791118
    Abstract: The invention provides new pyridopyrazine compounds according to formula (I) which are highly selective as Ras-Raf-Mek-Erk signal transduction pathway inhibitors and in particular are highly selective Erk inhibitors.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: July 29, 2014
    Assignee: Aeterna Zentaris GmbH
    Inventors: Matthias Gerlach, Irene Seipelt, Lars Blumenstein, Gilbert Mueller, Eckhard Guenther, Tilmann Schuster, Michael Teifel
  • Modulating signal transduction pathways with 1-ethyl-3-[3-(1-methyl-1H-pyrazol-4-yl)-pyrido[2.3-B]pyrazine-6-yl]thiourea
    Patent number: 8604196
    Abstract: A method of modulating one or more of ras-Raf-Mek-Erk signal transduction pathway, PI3K-Akt signal transduction pathway and SAPK signal transduction pathway with 1-ethyl-3-[3-(1-methyl-1H-pyrazol-4-yl)-pyrido[2,3-b]pyrazine-6-yl]thiourea, its geometric isomer, or its tautomer.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: December 10, 2013
    Assignee: Aeterna Zentaris GmbH
    Inventors: Matthias Gerlach, Irene Seipelt, Eckhard Guenther, Emmanuel Polymeropoulos, Tilmann Schuster, Eckhard Claus
  • Tetrahydrocarbazole derivatives as ligands of G-protein coupled receptors
    Patent number: 8541462
    Abstract: The present invention provides novel tetrahydrocarbazole compounds according to formula (I) as ligands of G-protein coupled receptors (GPCR) which are useful in the treatment and/or prophylaxis of physiological and/or pathological conditions in mammals mediated by GPCR or of physiological and/or pathological conditions which can be treated by modulation of these receptors.
    Type: Grant
    Filed: January 25, 2012
    Date of Patent: September 24, 2013
    Assignee: AEterna Zentaris GmbH
    Inventors: Tilmann Schuster, Klaus Paulini, Peter Schmidt, Silke Baasner, Emmanuel Polymeropoulos, Eckhard Guenther, Michael Teifel
  • Modulating signal transduction pathways with substituted pyridol [2,3-b] pyrazines
    Patent number: 8536332
    Abstract: Method of modulating ras-Raf-Mek-Erk signal transduction pathway, PI3K-Akt signal transduction pathway and/or SAPK signal transduction pathway with a pyrido[2,3-b]pyrazine of formula (Ia).
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: September 17, 2013
    Assignee: Aeterna Zentaris GmbH
    Inventors: Matthias Gerlach, Irene Seipelt, Eckhard Guenther, Emmanuel Polymeropoulos, Tilmann Schuster, Eckhard Claus
  • Pyridopyrazine derivatives, process of manufacturing and uses thereof
    Patent number: 8507486
    Abstract: 1-ethyl-3-[3-(1-methyl-1H-pyrazol-4-yl)-pyrido[2.3-b]pyrazine-6-yl]thiourea which HAS activity to the modulation of misdirected cellular signal transduction processes such as tyrosine kinases, serine/threonine kinases and/or lipid kinases.
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: August 13, 2013
    Assignee: Aeterna Zentaris GmbH
    Inventors: Matthias Gerlach, Irene Seipelt, Eckhard Guenther, Emmanuel Polymeropoulos, Tilmann Schuster, Eckhard Claus
  • Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
    Patent number: 8470776
    Abstract: The present invention provides conjugates of disorazoles and their derivatives with cell-binding molecules, such as peptides, proteins, hormones, blood proteins and antibodies. The present invention further provides novel disorazole derivatives and processes of manufacturing such conjugates and disorazole derivatives. These compounds can be used as medicaments for the treatment of physiological and/or pathophysiological conditions in mammals, in particular for the treatment of various tumors.
    Type: Grant
    Filed: March 19, 2010
    Date of Patent: June 25, 2013
    Assignee: Aeterna Zentaris GmbH
    Inventors: Eckhard Guenther, Olaf Schaefer, Michael Teifel, Klaus Paulini
  • NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES
    Publication number: 20130157976
    Abstract: The invention relates to novel pyrido[2,3-b]pyrazine derivatives of the general formulae (I) and (II), and to their preparation and use as medicaments, especially for the treatment of malignant disorders and other disorders based on pathological cell proliferations.
    Type: Application
    Filed: February 19, 2013
    Publication date: June 20, 2013
    Inventors: Eckhard CLAUS, Irene Seipelt, Eckhard Guenther, Emmanuel Polymeropoulos, Michael Czech, Tilmann Schuster
  • Naphthyridine derivatives and the use thereof as kinase inhibitors
    Patent number: 8461178
    Abstract: The present invention relates to kinase modulators of the naphthyridine type and to the preparation and use thereof as medicaments for the modulation of misdirected cellular signal transduction processes, in particular for influencing the function of tyrosine and serine/threonine kinases and for the treatment of malignant or benign tumors and other disorders based on pathological cell proliferation, such as, for example, restenosis, psoriasis, arteriosclerosis and cirrhosis of the liver.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: June 11, 2013
    Assignee: Aeterna Zentaris GmbH
    Inventors: Tilmann Schuster, Matthias Gerlach, Irene Seipelt, Emmanuel Polymeropoulos, Gilbert Mueller, Eckhard Guenther, Pascal Marchand, Julien Defaux
  • Quinoxaline derivatives and their use for treating benign and malignant tumour disorders
    Patent number: 8394801
    Abstract: The invention provides quinoxalines of the general formula I which are used as medicaments preferably for treating tumour disorders, in particular in cases of drug resistance to other active compounds and in cases of metastasic carcinoma. The possible applications are not limited to tumour disorders.
    Type: Grant
    Filed: March 25, 2010
    Date of Patent: March 12, 2013
    Assignee: Aeterna Zentaris GmbH
    Inventors: Matthias Gerlach, Irene Seipelt, Eckhard Guenther, Tilmann Schuster, Emmanuel Polymeropoulos, Michael Czech, Eckhard Claus
  • Use of alkylphosphocholines in combination with antitumor medications for the treatment of benign and malignant oncoses in humans and mammals
    Patent number: 8389497
    Abstract: The invention relates to the use of alkylphosphocholines in combination with antitumor medicaments for the treatment of benign and malignant oncoses in humans and animals. It is possible in this connection for the alkylphosphocholines to be employed in a combination according to the invention with one or a combination of various approved cytostatics. Preferred alkylphosphocholines are described by the Formula II.
    Type: Grant
    Filed: July 30, 2003
    Date of Patent: March 5, 2013
    Assignee: AEterna Zentaris GmbH
    Inventors: Jürgen Engel, Eckhard Günther, Herbert Sindermann
  • Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
    Patent number: 8383605
    Abstract: The invention relates to the use of alkylphosphocholines in combination with antimetabolites for the treatment of multiple myeloma, colon cancer or renal cancer. Preferred alkylphosphocholines are described by the Formula II. A particularly effective treatment includes administering a combination of perifosine and capecitabine.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: February 26, 2013
    Assignee: AEterna Zentaris GmbH
    Inventors: Jürgen Engel, Eckhard Günther, Herbert Sindermann, Babette Aicher
  • NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF
    Publication number: 20120277219
    Abstract: The invention relates to pyrido[2,3-b]pyrazine compounds of general formulae (Ia) and (Ib), to their preparation and use, for example, for the treatment of malignant disorders and other disorders based on pathological cell proliferations.
    Type: Application
    Filed: July 5, 2012
    Publication date: November 1, 2012
    Applicant: Aeterna Zentaris GmbH
    Inventors: Matthias Gerlach, Irene Seipelt, Eckhard Guenther, Emmanuel Polymeropoulos, Tilmann Schuster, Eckhard Claus
  • PYRIDOPYRAZINE DERIVATIVES AND THEIR USE
    Publication number: 20120258080
    Abstract: The present invention provides new pyridopyrazine compounds which are suitable for the treatment or prevention of physiological and/or pathophysiological states mediated and/or modulated by signal transduction pathways and/or enzymes in mammals and in particular in humans.
    Type: Application
    Filed: April 4, 2012
    Publication date: October 11, 2012
    Applicant: AETERNA ZENTARIS GmbH
    Inventors: Matthias GERLACH, Irene SEIPELT, Lars BLUMENSTEIN, Gilbert MUELLER, Eckhard GUENTHER, Tilmann SCHUSTER, Michael TEIFEL
  • PYRIDOPYRAZINE DERIVATIVES AND THEIR USE
    Publication number: 20120259151
    Abstract: The present invention provides new pyridopyrazine compounds which are suitable for the treatment or prevention of physiological and/or pathophysiological states mediated and/or modulated by signal transduction pathways and/or enzymes in mammals and in particular in humans.
    Type: Application
    Filed: April 4, 2012
    Publication date: October 11, 2012
    Applicant: AETERNA ZENTARIS GmbH
    Inventors: Matthias GERLACH, Irene Seipelt, Lars Blumenstein, Gilbert Mueller, Eckhard Guenther, Tilmann Schuster, Michael Teifel
  • NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES
    Publication number: 20120252760
    Abstract: The invention relates to novel pyrido[2,3-b]pyrazine derivatives of the general formulae (I) and (II), and to their preparation and use as medicaments, especially for the treatment of malignant disorders and other disorders based on pathological cell proliferations.
    Type: Application
    Filed: June 15, 2012
    Publication date: October 4, 2012
    Applicant: ZENTARIS GmbH
    Inventors: Eckhard Claus, Irene Seipelt, Eckhard Guenther, Emmanuel Polymeropoulos, Michael Czech, Tilmann Schuster
  • NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF
    Publication number: 20120214768
    Abstract: The invention relates to pyrido[2,3-b]pyrazine compounds of general formulae (Ia) and (Ib), to their preparation and use, for example, for the treatment of malignant disorders and other disorders based on pathological cell proliferations.
    Type: Application
    Filed: April 25, 2012
    Publication date: August 23, 2012
    Applicant: Aeterna Zentaris GmbH
    Inventors: Matthias Gerlach, Irene Seipelt, Eckhard Guenther, Emmanuel Polymeropoulos, Tilmann Schuster, Eckhard Claus
  • NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF
    Publication number: 20120209050
    Abstract: The invention relates to pyrido[2,3-b]pyrazine compounds of general formulae (Ia) and (Ib), to their preparation and use, for example, for the treatment of malignant disorders and other disorders based on pathological cell proliferations.
    Type: Application
    Filed: April 25, 2012
    Publication date: August 16, 2012
    Applicant: Aeterna Zentaris GmbH
    Inventors: Matthias GERLACH, Irene Seipelt, Eckhard Guenther, Emmanuel Polymeropoulos, Tilmann Schuster, Eckhard Claus
  • Pyridopyrazines and their use as modulators of kinases
    Patent number: 8217042
    Abstract: The invention relates to pyrido[2,3-b]pyrazines of the general formulae (I) and (II), and to their preparation and use as medicaments, especially for the treatment of malignant disorders and other disorders based on pathological cell proliferations.
    Type: Grant
    Filed: November 10, 2006
    Date of Patent: July 10, 2012
    Assignee: Zentaris GmbH
    Inventors: Eckhard Claus, Irene Seipelt, Eckhard Guenther, Emmanuel Polymeropoulos, Michael Czech, Tilmann Schuster